Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Image File
Original HTML

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.

The employee received, in the aggregate, non-qualified stock options to purchase 9,500 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $7.98 per share, the closing price of the Company's common stock as reported by Nasdaq on the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 4,750 shares of the Company's common stock, 25% of which will vest on the first anniversary of the grant date, and the remaining underlying shares will vest in 3 substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards."

All of the above-described Awards were granted pursuant to the 2026 Inducement Plan. The Awards were approved by the Human Capital Management Committee of the Company's Board of Directors, which is comprised solely of independent directors, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA) clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company's pipeline includes ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies. For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.

SOURCE Atrium Therapeutics

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302914657
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): The Target introduces unsourced legal/regulatory content: the statement that Nasdaq Listing Rule 5635(c)(4) governs inducement grants made outside shareholder-approved equity plans is not present in the SOURCE. All other factual metrics and vesting details match the SOURCE.
Source Name
Unknown Company
Original Summary

<p>SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to...</p>

Original Link
Original Source
Image URL
https://mmx.prnewswire.com/media/MS1799411/ATRIUM-Logo-RGB-Logo.jpg?id=OA3030414&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "Atrium Therapeutics Grants 9,500 Options in Nasdaq Inducement Award", "body_html": "<p><strong>San Diego -- [CURRENT_DATE] --</strong> Atrium Therapeutics (Nasdaq: RNA) granted a new non-executive hire non-qualified stock options on 9,500 shares at an exercise price of $7.98, plus restricted stock units (RSUs) covering 4,750 shares, under its 2026 Employment Inducement Incentive Award Plan.</p><h5>Options carry a $7.98 strike set at the Nasdaq closing price on the grant date</h5><p>The exercise price equals the closing price of Atrium's common stock, par value $0.001, as reported by Nasdaq on October 20, 2026. Atrium said the awards were a material inducement to the employee's hiring.</p><p>Twenty-five percent of the options vest on the first anniversary of the grant date. The remaining shares vest in 36 substantially equal monthly installments after that, provided the employee remains in service through each vesting date.</p><h5>RSUs for 4,750 shares vest over four years on an annual schedule</h5><p>Twenty-five percent of the RSUs vest on the first anniversary of the grant. The remainder vests in three substantially equal annual installments, again subject to continued service.</p><h5>Independent directors approved the grants under Nasdaq Listing Rule 5635(c)(4)</h5><p>The Human Capital Management Committee of Atrium's Board approved the awards. The committee consists solely of independent directors. Rule 5635(c)(4) is the Nasdaq provision that governs inducement grants made outside shareholder-approved equity plans.</p>", "meta_description": "Atrium Therapeutics (Nasdaq: RNA) granted 9,500 stock options at $7.98 and 4,750 RSUs to one new non-executive hire under its 2026 Inducement Plan on Oct. 20.", "seo_keywords": "Atrium Therapeutics, Nasdaq RNA, inducement grants, 2026 Inducement Plan, stock options, restricted stock units, Nasdaq Listing Rule 5635(c)(4), biotech hiring", "companies": ["Atrium Therapeutics"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["financial_disclosure", "corporate_governance"], "products": [], "themes": ["talent_acquisition", "executive_compensation"], "events": [], "cta_text": "Visit the Atrium Therapeutics website for more on the company", "learn_more": "https://atriumtherapeutics.com/", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
bab4e6721f9207f82180bc21229922ae